Epithelial ovarian carcinoma is the leading cause of death from gynecological malignancies. Owing to the lack of an effective screening method, insidious onset, and non-specific symptoms, a majority of women present with advanced stage disease. Despite improvements from cytoreductive surgery and chemotherapy, recurrent disease remains a formidable challenge. In the present study, we demonstrate for the first time that stable intra-abdominal genetic transfer of endostatin and angiostatin (E+A) by recombinant adeno-associated virus (rAAV) provides sustained antitumor effects on the growth and dissemination of epithelial ovarian cancer in a mouse model. Further, when combined with paclitaxel (taxol), the effect of this therapy was dramatically increased and resulted in long-term tumor-free survival overcoming prior limitations of chemotherapy and gene therapy. The combined effects of angiosuppressive therapy and chemotherapy were found to be independently of survivin pathway. Evidence for the superior effects of the combination therapy was indicated by significantly lower ascites volume with less hemorrhage and tumor conglomerates, lower ascites vascular endothelial growth factor, higher tumor cell apoptosis and decreased blood vasculature, and long-term disease-free survival. Histopathology of visceral organs and liver enzyme assays indicated no toxicity or pathology.
Introduction
Epithelial carcinoma of the ovary is the leading cause of death from gynecological malignancies accounting for more than 15 000 deaths per year in the US and is the second leading cause of death due to gynecological malignancies in the world. 1 The mortality associated with ovarian cancer is primarily due to dissemination of the disease within the peritoneal cavity to which conventional therapies such as surgery and chemotherapy fail to provide long-term cure. The disease normally presents at an advanced stage due to the absence of early diagnostic symptoms. Primary intervention for advancestage ovarian cancer is debulking surgery followed by chemotherapy with carboplatin/paclitaxel. 2, 3 Despite initial clinical response rate of 60-70%, most patients succumb to recurring chemoresistant disease. 4 In many patients with malignant ovarian disease, the final outcome is often determined by the spread of primary tumor to distant organs. 5, 6 Metastasis by hematogenous route is a multistep process that requires establishment of neovasculature, which is critical for survival and proliferation of the tumor. 7 Studies have confirmed that in the absence of angiogenesis, tumors rarely have the ability to develop beyond a few millimeters. 8 Among the autocrine and paracrine factors that promote angiogenesis, upregulation of vascular endothelial growth factor (VEGF) plays a key role in tumor neovasculature, and serves as a prognostic tool in advanced ovarian cancer. 9, 10 Thus, therapy directed against VEGF-induced tumor angiogenesis is a promising new area to conventional treatments including surgery and chemotherapy. Further, sustained antiangiogenic therapy when combined with primary treatments might provide efficacy gains in patients who undergo aggressive initial therapy.
Among different therapeutic modalities targeting tumor angiogenesis, gene therapy approaches have the potential to be more powerful than conventional pharmacological therapies. Unlike tumoricidal gene therapy approaches based on apoptotic gene transfer, molecular chemotherapy or conditionally replicating vectors intended for direct tumor cell killing, therapy targeting the growth and proliferation of endothelial cells is tumoristatic, hence, should be sustained. To this end, a vector capable of stable transduction of antiangiogenic genes without toxicity or vector-related immunity will be beneficial. Adeno-associated virus (AAV) is a promising alternative for stable expression of antiangiogenic factors. 11 Based on the advance-stage disease characteristics, pathological barriers of intraperitoneal (i.p.) dissemination and limitations of chemotherapy in epithelial ovarian cancer, the present study investigated the potential of intra-abdominal, sustained antiangiogenic gene therapy with endostatin and angiostatin (E+A) either as a standalone therapy or as a combination therapy to taxol in a preclinical mouse epithelial ovarian cancer model. Results of these studies demonstrated dramatic antitumor effects of the combination therapy over individual therapies. Significant effect of combining antiangiogenic gene therapy and taxol therapy was evident by decreased endothelial cell proliferation, ascites volume, ascites VEGF, increased tumor cell apoptosis and long-term tumor-free survival. Characterization of survivin expression in different groups also indicated that the antiangiogenic effects of E+A is independently of survivin pathway. Stable transduction of the vector in abdominal organs did not result in systemic or hepatotoxicity even in combination therapy suggesting the translational potential of this therapy in human patients.
Results
Effects of antiangiogenic gene therapy either as individual therapy or as combination therapy on tumor growth and survival
Results of survival are given in Figure 1 . It was interesting to note that animals treated with either rAAV-(E+A) or taxol alone exhibited marked increase in survival compared to naïve mice (Po0.02), and the survival index was highly comparable between the two treatments. However, animals in combination treatment group showed remarkably higher survival compared to both naive and rAAV-(E+A)-or taxol-treated mice (Po0.0001). The growth and behavior of mice in this group were indistinguishable from age-matched control mice, which did not receive either of the treatments or the tumor cells. The surviving animals were monitored for 240 days before terminating the experiment. Whereas mice in the naive group developed palpable tumors by day 11, those treated with either rAAV-(E+A) or taxol developed palpable tumors between days 24 and 26 after tumor implantation. There was no significant protective effect following rAAV-GFP treatment.
Primary tumors in the peritoneum were excised and weighed during necropsy. Mean tumor weight in the naive group was 1600 mg and that in rAAV-GFP groups was 1420 mg. The mean tumor weight in paclitaxeltreated mice during the same time was 650 mg (Po0.001) and in rAAV-(E+A)-treated mice was 760 mg (Po0.03). In the group of mice that received both rAAV-(E+A) and paclitaxel, the mean tumor mass was 150 mg (Po0.0001).
Effects of rAAV antiangiogenic gene therapy on ascites volume and VEGF levels
Ascites volume was determined in untreated and rAAV-(E+A)-, taxol-, and rAAV-(E+A) plus taxol-treated groups when animals in untreated group showed enlarged abdomen and loss of body weight by over 10% compared to age-matched control mice that were not implanted with tumor cells. As shown in Figure 2a , the mean ascites volume in untreated mice was 1.7 ml. The ascites volume was significantly reduced in animals that were given taxol or rAAV-(E+A) with quantities of 0.2 and 0.3 ml, respectively (Po0.001). The amount of ascitic fluid was significantly reduced in animals treated with both taxol and rAAV-(E+A) (0.05 ml, Po0.0001 compared to naive mice). Whereas ascites from untreated animals was highly hemorrhagic, that from taxol, rAAV-(E+A) or rAAV-(E+A) plus taxol was less hemorrhagic and markedly clear.
A strong correlation on the effects of VEGF in malignant ascites formation in human epithelial ovarian cancer has been documented in earlier studies. 12, 13 To determine the effects of stable antiangiogenic gene therapy on VEGF production and to correlate ascites VEGF levels to ascites volume and tumor burden, VEGF levels were determined in ascites of naive and rAAV-(E+A)-and/or taxol-treated mice. As the volume of ascites in different groups of mice differed significantly, the VEGF levels were expressed as ng/ml ascitic fluid. Results of enzyme linked immunosorbent assay (ELISA) analysis of ascites from different groups are given in Figure 2b . Highest VEGF was observed in the ascites of naïve animals with a mean value of 19.2 ng/ml. There was a significant reduction in ascites VEGF in taxol-(5.5 ng/ml) or rAAV-E+A-(5.1 ng/ml) treated animals compared to naive mice (Po0.003) although there was no significant difference between the two treatments, and in combination therapy, VEGF level was further decreased (0.6 ng/ml) compared to naive animals (Po0.0001). Intraperitoneal gene therapy by rAAV T Isayeva et al ELISA measurement of circulating human endostatin indicated mean values of 272 and 275 ng/ml in rAAV-(E+A)-and rAAV-(E+A) plus taxol-treated animals, respectively. The endostatin levels were achieved 3 weeks after vector injection and remained steady until killing of the animals due to either tumor burden or termination of the experiment (data not shown).
Inhibitory effects of antiangiogenic gene therapy and chemotherapy on proliferation of ovarian cancer and tumor endothelium
As the mechanism of action of taxol and E+A is through different pathways, [14] [15] [16] [17] [18] we hypothesized that combined effects of these two therapies may result in a better therapeutic outcome. To determine this, immunohistochemistry was performed on tumor tissues from naive, rAAV-(E+A)-, taxol-and rAAV-(E+A) plus taxol-treated mice. Tumor samples used in immunohistochemistry were obtained from mice in different groups when mice in the naive group were killed due to tumor burden. Ki67 staining was performed for proliferation index and poly ADP-ribose polymerase (PARP) p85 fragment staining for apoptosis. Results of these analyses are given in Figure 3a . Highest tumor cell proliferation was observed in naive mice. Significant reduction in tumor proliferation was observed in taxol-or rAAV-(E+A)-treated animals (Po0.03). However, there was no statistically significant difference in the proliferation index among the two treatment groups (P40.05). The apoptotic index was higher in rAAV-(E+A)-and taxol-treated mice, compared to naive animals (Po0.001) and the apoptosis index was more pronounced in combination therapy, which was significantly higher than both of the individual therapies and the naive group ( Figure 3b ).
To determine direct or indirect effects of rAAV antiangiogenic therapy and/or taxol therapy on endothelial cell proliferation, immunohistochemistry was performed using CD31 antibody. The results are given in Figure 3 . Tumor tissues obtained from naïve mice showed higher index of proliferating blood vasculature compared to individual therapies. The difference was more pronounced following combination therapy. 
Intraperitoneal gene therapy by rAAV T Isayeva et al
Vector biodistribution, histopathology and toxicity analyses Unlike the previous studies, which utilized the skeletal muscle or the liver for the production of rAAV transgene proteins, [19] [20] [21] [22] [23] [24] [25] the present study is the first preclinical validation of i.p. transduction of rAAV encoding therapeutic transgenes. Hence, we determined that despite a successful outcome on survival, it was important for us to determine target cells in the peritoneum, transduced by the vector, and if vector transduction results in visceral or systemic pathology. Vector biodistribution was determined by semiquantitative real-time PCR using transgene-specific primers. Results of these studies are given in Figure 4a . Significant copies of vector genome were found in ovary, muscle, intestine and lymph node. However, it should be noted that real-time PCR analysis performed in this study does not indicate transcriptionally active copies of the genome or integration frequency. Histopathological analysis of hematoxylin and eosin (H&E) stained sections of ovary, kidney, liver and spleen did not indicate any abnormality such as increased necrosis or apoptosis due to combination therapy, compared to control mice that did not receive either vector or tumor cells (Figure 4b ). Similar observations were also made in individual therapies (data not shown). To further determine whether peritoneal mesothelial cells express E+A from rAAV, we stained the peritoneal wall immunohistochemically with E+A antibodies. Results, shown in Figure 4c demonstrated a significant proportion of cells expressing the transgene protein even after 240 days. The expression of endostatin in situ by immunohistochemistry correlated with vector genome quantified from different peritoneal tissues (data not shown). Measurement of serum alanine aminotransferase (ALT) as indicator of liver function indicated no significant elevation in combination treatment compared to paclitaxel treatment alone although at given paclitaxel dose, there was moderate elevation (P40.05) in the level of serum aspartate compared to age-matched control mice (Figure 4d ).
Growth inhibitory effect of antiangiogenic gene therapy is independently of upregulated survivin expression following taxol resistance
To characterize the induction of survivin by taxol, a hallmark in chemoresistant cancers, 26, 27 in SKOV3.ip1 cells, we first determined the effects of taxol on survivin expression in vitro. Results of these studies indicated that taxol treatment of SKOV3.ip1 cells results in upregulation of survivin ( Figure 5 ). Transduction of these cells with rAAV-(E+A) before taxol treatment did not alter survivin expression significantly. Data from immunohistochemical staining were also corroborated by Western blot analysis (data not shown). Further, to determine if taxol-induced survivin expression in SKOV3.ip1 cells is an early event of the cell cycle and independent of microtubule stabilization and mitotic arrest, the cells were analyzed by staining with b-tubulin antibody. Results of this analysis, also shown in Figure 5 , indicated that induction of survivin by taxol is concomitant to Intraperitoneal gene therapy by rAAV T Isayeva et al microtubule stabilization. Based on this information from the in vitro studies, we determined if antiangiogenic gene therapy, either alone or in combination with chemotherapy in i.p. ovarian cancer is influenced by survivin pathway. Expression of survivin in tumor tissues obtained from naive, taxol-, rAAV-(E+A)-and rAAV-(E+A) plus taxol-treated mice was analyzed by immunohistochemical staining. Results, shown in Figure 6 , indicated that mice that showed taxol resistance had higher levels of survivin expression compared to the group that did not receive taxol. Although combination treatment with taxol and rAAV-(E+A) resulted in significant decrease in tumor and endothelial cell proliferation, and an increase in tumor cell apoptosis (Figure 3 ), survivin expression was not concomitantly decreased.
Discussion
Gene therapy is a promising alternative for increasing survival of ovarian cancer patients. Despite its potential, several limitations associated with both technical impediments of currently available vector systems including duration of transgene expression and lack of optimal targeted delivery, and complications of the anatomical barriers in advance stage ovarian disease, pose great challenge. For the last few decades, surgery followed by platinum-based chemotherapy remains the only palliative intervention with a mean survival rate of 5 years. As most neoplasms involve multiple mutations, targeting a single mutation is unlikely to achieve total tumor control.
Gene therapy strategies that target multiple cellular processes or invoke various antitumor approaches thus need to be investigated. Additionally, current vector systems do not transduce ovarian cancer cells efficiently and are hampered by immune responses that further limit their efficacy. 28 Hence, development of more effective interventional strategies which target associated physiological events that favor i.p. ovarian cancer growth and dissemination would be hopeful alternatives as newer therapies.
The effects of VEGF during the development of human ovarian carcinoma have been studied by many groups, which indicated that VEGF plays a pivotal role during malignant ascites formation by increasing the vascular permeability, and tumor growth and metastasis. 9, 10, [29] [30] [31] [32] [33] Whereas other inflammatory factors such as prostaglandins, bradykinin, 34 leukokinins, 34 histamine and other cytokines [34] [35] [36] [37] have also been associated with increased permeability, VEGF has been identified as the causative factor for malignant ascites formation, and VEGF targeted therapies have provided significant inhibitory effects on tumor growth. Although several drugs and small molecule inhibitors of VEGF are being clinically tested, their efficacy as stand-alone therapy has been very dismal in advance stage disease due to short half-life and dose-limiting toxicities. Taxol induces mitotic arrest through polymerization and stabilization of microtubules. [38] [39] [40] Tubulin mutations, which result in alterations in either the assembly or stability of microtubules can lead to taxol resistance. 41, 42 Data from our in vitro studies clearly demonstrate such a mechanism in SKOV3.ip1 cells. Thus, therapy targeting tumor endothelium could provide distinct advantage to inhibit the aggressive growth of chemoresistant ovarian cancer. This is evident from our in vivo studies, which indicated significant antitumor and long-term benefits following rAAV-(E+A) therapy, in particular, as a Intraperitoneal gene therapy by rAAV T Isayeva et al combination therapy to taxol despite higher survivin expression. Although taxol is highly effective during the initial phase of therapy as evident by significantly reduced amounts of ascites volume, ascites VEGF, tumor cell proliferation and increased apoptosis, taxol resistant growth of SKOV3.ip1 tumor appeared on day 25-30 and the animals died around day 60. Interestingly, animals treated with antiangiogenic gene therapy alone also showed survival as well as significantly reduced ascites, ascites VEGF, tumor cell proliferation and increased apoptosis, highly comparable to the taxoltreated group. This observation suggests that although sustained expression of E+A can exert growth inhibition of tumor cells, the pathophysiology of ovarian cancer is highly disseminative, which may limit the required amount of transiently produced antiangiogenic factors from reaching the disseminative tumor growth. This is correlative to our earlier findings that although stable systemic levels of E+A by intramuscular administration of the vector provided highly significant growth inhibition of subcutaneous tumors, 20 and i.m. administration of rAAV encoding soluble Flt-1 was also highly inhibitory for the growth of subcutaneously implanted human ovarian cancer cells in mice 22 a similar approach indicated only moderate effects against i.p. tumors. 23 Thus, it is apparent that for antitumor effects on i.p. growth and dissemination of ovarian cancer by antiangiogenesis, a more effective route of vector administration is required. Although the apoptotic index of combination therapy was higher compared to individual therapies, the difference was not dramatic. Thus, we believe synergistic inhibition of endothelial cell proliferation observed in combination treatment should have augmented long-term antitumor effects.
Results of the present study also suggest that initial treatment with taxol provides a crucial adjuvant effect to overcome the limitations of antiangiogenic therapy alone. Thus, we believe i.p., stable rAAV-(E+A) gene therapy can better serve as an adjuvant therapy in human patients when administered along with chemotherapy following surgical debulking. Although the present study demonstrates the potential of combination taxol and rAAV encoding E+A for i.p. ovarian cancer growth and dissemination, few important considerations need to be addressed prior to clinical translation of this approach. Foremost is the duration of transgene expression following rAAV therapy without any negative effects. One of the limitations in preclinical ovarian cancer studies is the lack of appropriate animal models with spontaneous disease occurrence. Thus, the effects of host immune response against the vector need to be carefully monitored for establishing long-term feasibility, which is a limitation in studies with immunodeficient mice. Unlike other viral vectors currently used in gene therapy, AAV-based vectors are entirely devoid of genes encoding vector structural proteins. 43 Also, the availability of newer AAV serotypes, identified from nonhuman primate tissues, yet displaying high transduction efficiency and low pre-existing immunity in humans 44, 45 would be useful alternates if pre-existing immunity poses a limitation for repeat administration. Another concern of sustained expression of antiangiogenic proteins is its pathological and physiological consequences including wound healing. Recent studies have established that therapy with purified endostatin at concentrations of up to 300 mg/m 2 did not result in systemic toxicity or impair wound healing in humans. 46 Hence, therapeutically stable levels of expression of E+A may not prove deleterious. Nonetheless, these concerns can be negated by using inducible promoters, which have proven efficacious in preclinical murine and non-human primate studies using rAAV. 47, 48 Paclitaxel is also known to cause genotoxic effects on bone marrow cells. 49, 50 Thus, optimizing dose of taxol treatment for combination therapy without causing significant toxicity will be important. Noteworthy observation in the present study is paclitaxel, administered only two times, provided significant long-term survival in combination with sustained expression of E+A. Thus, this combination therapy may provide better efficacy gains with low-dose chemotherapy in human patients.
Materials and methods

Cells and reagents
Human embryonic kidney cell line, 293, was purchased from American Type Culture Collection and maintained in Iscove's modified essential medium supplemented with 10% newborn calf serum. The human epithelial ovarian cancer cell line SKOV3.ip1 was a gift from Dr Janet Price (MD Anderson Cancer Center, Houston, TX, USA) and was maintained in Eagle's Minimal Essential Medium (EMEM) containing non-essential amino acids, 1 mM sodium pyruvate and 10% fetal bovine serum. The cells were cultured in 371C with 5% CO 2 . The SKOV3.ip1 cells were harvested from subconfluent culture by brief exposure to 0.25% trypsin, stopped with medium, containing 10% serum, washed twice and resuspended in phosphate buffer solution (PBS). Only single-cell suspensions with 495% viability were used for in vivo injection.
Restriction endonucleases and other modifying enzymes were purchased from either New England Biolabs (Beverly, MA, USA) or Promega Corporation (Madison, WI, USA). Mouse monoclonal antibody for Ki67 (clone SP6) and rabbit polyclonal antibody for PARP p85 fragment were obtained from Research Diagnostics Inc., and Promega, respectively. Monoclonal antibodies for survivin (clone FL-142) and tubulin (clone TUJ-1) were purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA and Covance Inc., Princeton, NJ, USA, respectively. Secondary antibodies and color reagents were purchased from Molecular Probes, Eugene, OR, USA. Mouse VEGF ELISA kit was purchased from R&D System Inc., Minneapolis, MN, USA.
Recombinant plasmids, production and purification of rAAV Construction of recombinant plasmids containing secretable forms of human E+A as bicistronically expressed proteins and that encoding green fluorescence protein (GFP) was recently published. 20 In rAAV-(E+A) construct, to allow extracellular secretion of endostatin the human IL-2 secretory signal was included and for angiostatin the human plasminogen signal sequence was included. Production and purification of rAAV was carried out by transient transfection in 293 cells followed by iodixanol gradient centrifugation and Intraperitoneal gene therapy by rAAV T Isayeva et al heparin-affinity column chromatography. 51 The particle titer of purified virions was determined by quantitative slot blot analysis. 52 In vitro analysis of taxol-induced survivin expression in SKOV3.ip1 cells SKOV3.ip1 cells were seeded in 12-well tissue culture dishes (Corning 3513) and treated with taxol (Sigma Chemical Co, St Louis, MO, USA) at a concentration of 100 nm. Stock solution of taxol was made in Dimethyl Sulfoxide (DMSO) and stored at À201C. Before taxol treatment of the cells, the stock solution was diluted and resuspended in EMEM. The cells were treated with taxol for 12 h before analysis. Vector transduction was performed 48 h before taxol treatment by using 100 multiplicity of infection (MOI) of rAAV-(E+A). For immunohistochemical staining with survivin and tubulin antibodies, cells were fixed in buffered-formaldehyde. Survivin and tubulin antibodies were used at dilutions of 1:50 and 1:500, respectively, followed by treatment with Alexa Fluor-labeled goat anti-rabbit or goat anti-mouse secondary antibodies at 1:200 dilution. The stained slides were analyzed in an Olympus microscope.
In vivo studies
Female athymic nude mice (6-week-old) were purchased from the National Cancer Institute-Frederick Animal Production Area (Frederick, MD, USA). All the animal studies were carried out in accordance to the guidelines of Institutional Animal Care and Use Committee (IACUC) and all experimental procedures were approved by IACUC and the Occupational Health and Safety Department of the University of Alabama at Birmingham. Each group consisted of at least 18 mice. Three mice from each group were killed when naive animals showed tumor burden requiring euthanasia, for histology, immunohistochemistry, toxicity analyses and ELISA measurements. Remaining animals (a minimum of 10) in the surviving groups were monitored for longterm survival. Approximately 10 11 genomic particles of rAAV encoding GFP or E+A, in normal saline, were injected in a volume of 100 ml i.p. Naive animals did not receive any vector. Three weeks after vector administration, each mouse received 10 7 SKOV3.ip1 cells by i.p. injection.
For cohorts of mice receiving chemotherapy, taxol was i.p. administered at a concentration of 20 mg/kg on days 11 and 14 after tumor cell implantation. The onset of i.p. tumors was determined based on significantly increased abdominal circumference due to ascites. Comparisons were made between animals in the control (mice without rAAV or tumor challenge), naive (mice with SKOV3.ip1 cells but no rAAV) and rAAV-(E+A)/ taxol plus SKOV3.ip1 groups for abdominal volume. The abdominal area was carefully checked to detect palpable tumors. The animals were monitored twice every week for body weight and tumor formation in the peritoneal cavity and were euthanized when they became moribund, the day of euthanasia considered as the limit of survival. Ascitic fluid and peritoneal tissues were harvested for further analyses. Weight of solid peritoneal tumors and ascites volumes were recorded. Blood samples were collected from all animals before vector administration, before tumor cell implantation, and at killing.
Immunohistochemistry
Immunohistochemical studies were performed in 5 mm sections of paraffin-embedded tumor tissues using antibodies for Ki67 and anti-PARP p85 for proliferation and apoptosis, respectively. Survivin expression was analyzed by staining with a rabbit anti-human antibody (Santa Cruz). Antigen retrieval was achieved by incubating the slides in 0.05% trypsin for 20 min at 371C and endogenous peroxidase was blocked by incubation with 3% H 2 O 2 for 10 min at room temperature. The antibodies were in a working dilution of 1:50. Further, the slides were stained with donkey anti-rabbit horseradish peroxidase-linked secondary antibody (1:500 dilution). The antigen-antibody complex was visualized with diaminobenzidine tetrahydrochloride and slides were counterstained minimally with hematoxylin. To determine the proliferation and apoptotic indices, stained slides were examined under high-power ( Â 40). A minimum of 10 randomly chosen fields were counted to determine the total number of cells and that stained positive in each field. The percentage proliferation and apoptosis was calculated using the formula: (number of positively stained cells/total number of cells in a field) Â 100. Secondary antibody used for the detection of survivin was Alexa Fluor-conjugated anti-rabbit IgG (H+L, Molecular Probes) at a dilution of 1:500. Diamidino-2-phenylindole hydrochloride (DAPI) staining of the sections was performed to determine the viable cell density. Immunohistochemical analysis of the peritoneal wall, to demonstrate the expression of rAAV-E+A was performed as described. 20 
Enzyme linked immunosorbent assay
Ascitic fluid was harvested on the day of killing of the animals due to tumor burden and the volume measured. The ascitic fluid was briefly centrifuged to remove loose cells and the supernatant frozen at À801C until analysis. The VEGF levels in ascites were determined using a commercial ELISA kit (R&D System Inc.), which recognizes the 164 and 120 amino-acid residues of mouse VEGF. Systemic levels of human endostatin were measured in serum samples prior to tumor challenge, before rAAV injection and during killing, as described. 20 All assays were performed in triplicate.
Semiquantitative real-time PCR analysis for vector genome
Total DNA was isolated from intra-abdominal organs including ovary, muscle, liver, kidney, spleen, intestine and adipose tissue as described. 50 Semiquantitative realtime PCR was performed using CMV promoter-specific primers in a Biorad iCycler (Optical Module). Reactions were performed using the LightCycler-FastStart DNA Master SYBR Green system (Roche Molecular Biochemicals, Mannheim, Germany) in a final volume of 25 ml, consisting of 0.5 ml of each primer (0.5 pM), 12.5 ml of 2 Â supermix containing reaction buffer, Fast-start Taq DNA double-strand-specified SYBR Green I dye, 5.5 ml H 2 O and 5 ml (0.5 mg) of template DNA. The following primers were used for the amplification of vector-specific sequences and endogenous mouse GAPDH gene: CMV promoter forward: 0 . Polymerase chain reaction (PCR) was performed with a 3 min pre-incubation at 951C followed by 45 cycles of 15 s denaturation at 951C, and 30 s annealing and extension at 571C. PCR products were subjected to melting curve analysis using the light cycler system to exclude amplification of non-specific products. Values obtained from amplification of vector-specific sequences from each sample were normalized to copy number of GAPDH gene amplification from the same sample to derive the relative vector copy number per cell.
Toxicity analysis
Hepatic toxicity was assessed by quantitative measurement of serum ALT using a commercial kit (TECO Diagnostics, Anaheim, CA, USA), and histopathology of serial liver sections by H&E staining as described. 23 The effects of rAAV treatment in other major peritoneal organs including the intestine, kidney, ovary, spleen and peritoneal wall were also determined histopathologically by H&E staining of tissues obtained from control and rAAV-treated mice.
Statistical analysis
Data were compiled as mean7s.e. in quantitative experiments. For statistical analysis of differences between the groups, an unpaired Student's t-test was performed. P-values o0.05 were considered to indicate significant difference between data sets.
